Observational studyOpen heart2026
Impact of a durable left ventricular assist device on inflammation and cardiac remodelling in subjects with advanced heart failure.
Observational study in Open heart, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to explore the association of long-term left ventricular assist device (LVAD) support with changes in inflammation and cardiac remodelling in subjects with advanced heart failure (HF).
methodsA single-centre prospective observational trial was conducted in 16 consecutive subjects with advanced HF who were indicated for implantation of HeartMate 3 LVAD. Blood samples were collected both during the procedure (V1) and 12 months postoperatively (V2) for comprehensive analysis. Additionally, in a subgroup of seven LVAD subjects listed for heart transplantation (HTx), a histological examination was performed on myocardial samples obtained during LVAD implantation and from the explanted heart following HTx.
resultsLVAD implantation was associated with reductions in brain natriuretic peptide (324.7±47.0 vs 124.6±50.3 pg/mL) and C reactive protein (15.2±3.8 vs 6.0±1.3 mg/L) levels. Decreased inflammation markers coincided with reduced levels of lymphocyte- and macrophage-derived cytokines and their stimulating factors. LVAD implantation was associated with modulation of circulating biomarkers related to negative cardiac remodelling processes, including reductions in fibrosis- and remodelling-associated mediators (Extracellular Matrix Metalloproteinase Inducer, fibroblast growth factor (FGF)-2, FGF-19, receptor for advanced glycation endproducts, suppression of tumourigenicity 2, interleukin 27) and angiogenesis-related factors (stromal cell-derived factor-1α, growth differentiation factor (GDF)-15, somatotropin, vascular endothelial growth factor, angiopoietin 1, hepatocyte growth factor). In parallel, markers of metabolism and systemic catabolic state were significantly modulated, with decreases in GDF-15, somatotropin, trefoil factor 3 and resistin and increases in leptin levels. Histological analysis of myocardial samples available from a subgroup of subjects showed reduced macrophage infiltration following LVAD implantation.
conclusionsLong-term LVAD support was associated with improved biochemical and haematological profiles and with coordinated changes in circulating markers of inflammation, metabolism and cardiac remodelling. These exploratory findings provide further insight into the biological changes associated with durable mechanical unloading in subjects with advanced HF.
Indexed as
Identifiers
42580841What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.